Q4 2024 Management View CEO Ryals McMullian highlighted strong performance in branded bread, driven by innovation and market execution, but acknowledged weaker-than-expected sales due to persistent ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.